Effects of short term metformin administration on androgens in diabetic men

Saudi Medical Journal

Volumn 25, Issue 1, 2004, Pages 75-78

  Shegem, Nadima S ^a   Alsheek Nasir, Abeer M ^a   Batieha, Anwar M ^b   El Shanti, Hatem ^b   Ajlouni, Kamel M ^a  

^a JORDAN UNIVERSITY HOSPITAL   (Jordan)

^b JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; FOLLITROPIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HYDROXYPROGESTERONE; INSULIN; LUTEINIZING HORMONE; METFORMIN; ORAL ANTIDIABETIC AGENT; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG MECHANISM; FOLLITROPIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HORMONE METABOLISM; HUMAN; INSULIN BLOOD LEVEL; JORDAN; LUTEINIZING HORMONE BLOOD LEVEL; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SHORT COURSE THERAPY; TESTOSTERONE BLOOD LEVEL; UNIVERSITY HOSPITAL;

ADMINISTRATION, ORAL; ADULT; ANDROGENS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; GONADOTROPINS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PROBABILITY; REFERENCE VALUES; SAMPLING STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 1342268291     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetic Review 1998; 6: 89-131.
2. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137: 25-33.
3. Dorella M, Giusto M, Da Tos V, Campagnolo M, Palatini P, Rossi G, et al. Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of non-obese insulin-resistant hypertensive patients with normal glucose tolerance. J Clin Endocrinol Metab 1996; 81: 1568-1574.
4. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean non-insulin-dependant diabetic subjects. J Clin Endocrinol Metab 1991; 73: 1294-1301.
5. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in non-insulin-dependant diabetes mellitus. J Clin Endocrinol Metab 1996; 81: 4059-4067.
6. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865.
7. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandregenemia and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994; 43: 647-654.
8. De Leo V, La Marca A, Orvieto R, Morgante G. Effect of metformin on insulin-like growth factor (IGF) 1 and IGF-Binding protein 1 in polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85: 1598-1600.
9. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, et al. Effect of long term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85: 2767-2774.
10. Shegem NS, Nasir AM, Jbour AK, Batieha AM, El-Khateeb MS, Ajlouni KM. Effect of short-term metformin administration on androgens in normal men. Saudi Med J 2002; 23: 934-937.
11. Ozata M, Oktenli C, Bingol N, Ozdemir IC. The effects of metformin and diet on plasma testosterone and leptin levels in obese men. Obesity Research 2001; 9: 662-667.
12. Report of the expert committee on diagnosis and classification of diabetes mellitus. Diabetes 1997; 20: 1183.
13. Marfella R, Acampora R, Verrazzo G, Ziccardi P, De Rosa N, Giunta R, et al. Metformin improves hemodynamic and rheological responses to L-arginine in NIDDM patients. Diabetes Care 1996; 19: 934-939.
14. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endorinol Metab 1997; 82: 524-530.
15. Jansson PA, Gudbjornsdottir HS, Andersson OK, Lonnroth PN. The effect of metformin on adipose tissue metabolism and peripheral blood flow in subjects with NIDDM. Diabetes Care 1996; 19: 160-164.
16. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755-772.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
18. Nestler JE. Sex hormone-binding globulin: a marker for hyperinsulinemia and/or insulin resistance? J Clin Endocrinol Metab 1993; 76: 273-274.
19. Peiris AN, Stagner JI, Plymate SR, Vogel RL, Heck M, Samols E. Relation of insulin secretory pulses to sex hormone-binding globulin in normal men. J Clin Endrinol Metab 1993; 76: 279-282.
20. Preziosi P, Barrett-Connor E, Papoz L, Roger M, Saint-Paul M, Nahoul K, et al. Interrelation between Plasma Sex Hormone-Binding Globulin and Plasma Insulin in Healthy Adult Women: The Telecom Study. J Clin Endrinol Metab 1993; 76: 283-287.
21. Birkeland KI, Hanssen KF, Torjesen PA, Vaaler S. Level of sex hormone-binding globulin is positively correlated with insulin sensitivity in men with type 2 diabetes. J clin Endocrinol Metab 1993; 76: 275-278.
22. Goodman-Gruen D, Barrett-Connor E. Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. Diabetes Care 2002; 23: 912-918.
23. Nestler EJ, McClanahan MA, Clore JN, Blackard WG. Blackard. Insulin inhibits adrenal 17, 20 -lyase activity in man. J Clin Endorinol Metab 1992; 74: 362-367.
24. Ueshiba H, Shimizu Y, Hiroi N, Yakushiji F, Shimojo M, Tsuboi K, et al. Decreased steroidogenic enzyme. 17-20-lyase and increased 17-hydroxylase activities in type 2 diabetes mellitus. Eur J Endocrinol 2002; 146: 375-380.